Richmond Brothers, Inc.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 12, 2024), Richmond Brothers, Inc. reported 22 stock positions worth $50.6 million. Its top holding was Invesco QQQ Trust Series 1 (QQQ) at 36.7% of the portfolio, followed by Mimedx (MDXG, 12.6%) and Apple (AAPL, 11.6%). Compared with Q1 2024, it opened 2 new positions, sold out of 4, added to 3 and reduced 11. The biggest buy was Durect (DRRX, shares +40%) and the biggest sale Mimedx (MDXG, shares −16%).
- Most Recent 13F
- Q2 2026
- Location
- JACKSON, MI
- CIK
- 0001540462
- Portfolio Value
- $50.6M (Q2 2024)
- SEC Filing
- 0001085146-24-003720 ↗ filed Aug 12, 2024
Holdings Value
Holdings 22 stocks · $50.6M
| QQQ Invesco QQQ Trust Series 1 | 36.67% | 38,703 | $18.5M | Reduce -7.8% |
| MDXG Mimedx Group Inc. | 12.57% | 917,343 | $6.4M | Reduce -16.4% |
| AAPL Apple Inc. | 11.56% | 27,758 | $5.8M | Reduce -7.9% |
| BRK.B Berkshire Hathaway Inc. Class B | 10.25% | 12,742 | $5.2M | Reduce -7.0% |
| GOF Guggenheim Strategic Opport | 8.75% | 296,824 | $4.4M | Reduce -1.8% |
| MSFT Microsoft Corp. | 4.02% | 4,544 | $2.0M | Reduce -11.3% |
| DRRX Durect Corporation | 2.73% | 1,072,014 | $1.4M | Add +39.5% |
| HRTX Heron Therapeutics Inc. | 2.47% | 356,558 | $1.2M | Add +20.2% |
| IBB iShares Biotechnology ETF | 1.98% | 7,290 | $1.0M | Reduce -11.6% |
| NVG Nuveen Amt-FR Muni CRDT | 1.08% | 44,024 | $549K | Reduce -4.0% |
| TQQQ Proshares Ultrapro QQQ | 1.08% | 7,373 | $544K | Add +31.4% |
| AMZN Amazon.com Inc. | 1.07% | 2,797 | $541K | No change |
| IVV iShares Core S&P 500 ETF | 0.98% | 902 | $494K | Reduce -0.7% |
| RMTI Rockwell Medical Inc. | 0.96% | 276,828 | $487K | Reduce -14.1% |
| GOOG Alphabet Inc. Class C | 0.72% | 1,984 | $364K | No change |
| AXONICS INC | 0.63% | 4,749 | $319K | No change |
| IRD Opus Genetics Inc. filed as OCUPHIRE PHARMA INC | 0.58% | 191,304 | $293K | Reduce -15.9% |
| APLT Applied Therapeutics Inc. | 0.57% | 61,827 | $289K | No change |
| MCD McDonald's Corp. | 0.48% | 948 | $242K | No change |
| ONCT Oncternal Therapeutics Inc. | 0.37% | 24,696 | $188K | No change |
| ALVO Alvotech SA | 0.34% | 13,966 | $170K | New |
| SOFI Sofi Technologies Inc. | 0.13% | 10,083 | $67K | New |
Portfolio Sells Q1 2024 → Q2 2024
| MDXG Mimedx Group Inc. | Reduce -16.4% | 12.57% | −3.08 |
| ARKK ARK Innovation ETF | Sold out | 0.00% | −2.94 |
| BRK.B Berkshire Hathaway Inc. Class B | Reduce -7.0% | 10.25% | −0.42 |
| PG The Procter & Gamble Co. | Sold out | 0.00% | −0.39 |
| VZ Verizon Communications Inc. | Sold out | 0.00% | −0.38 |
| AIRI Air Industries Group | Sold out | 0.00% | −0.30 |
| IRD Opus Genetics Inc. | Reduce -15.9% | 0.58% | −0.27 |
| IBB iShares Biotechnology ETF | Reduce -11.6% | 1.98% | −0.12 |
| RMTI Rockwell Medical Inc. | Reduce -14.1% | 0.96% | −0.03 |
| MSFT Microsoft Corp. | Reduce -11.3% | 4.02% | +0.02 |
| NVG Nuveen Amt-FR Muni CRDT | Reduce -4.0% | 1.08% | +0.05 |
| IVV iShares Core S&P 500 ETF | Reduce -0.7% | 0.98% | +0.09 |
| GOF Guggenheim Strategic Opport | Reduce -1.8% | 8.75% | +0.73 |
| AAPL Apple Inc. | Reduce -7.9% | 11.56% | +1.98 |
| QQQ Invesco QQQ Trust Series 1 | Reduce -7.8% | 36.67% | +2.13 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 96 | $192.3M | QQQ, AAPL, NVDA, MSFT, VGT |
| Q1 2026 | 36 | $150.2M | QQQ, VDE, VPU, VAW, VIS |
| Q4 2025 | 36 | $157.2M | QQQ, VOX, VHT, VGT, VFH |
| Q3 2025 | 34 | $158.4M | QQQ, VOX, VPU, VGT, BSV |
| Q2 2025 | 30 | $152.7M | QQQ, BSV, BIV, VPU, VOX |
| Q1 2025 | 31 | $158.2M | BSV, BIV, VTIP, QQQ, BIL |
| Q4 2024 | 32 | $156.0M | QQQ, BIL, VOX, VCR, VFH |
| Q3 2024 | 33 | $162.2M | QQQ, BIL, VPU, VOX, VIS |
| Q2 2024 | 22 | $50.6M | QQQ, MDXG, AAPL, BRK.B, GOF |
| Q1 2024 | 24 | $54.0M | QQQ, MDXG, BRK.B, AAPL, GOF |